Multiple sclerosis (MS) is the most common idiopathic inflammatory dis
ease of the central nervous system. The distinction between MS and oth
er benign or fulminant inflammatory demyelinating disorders is based o
n quantitative, rather than qualitative, differences in chronicity and
severity. Primary progressive MS may differ from relapsing-remitting
MS in MRI lesion frequency, immunogenetic profile, responsiveness to i
mmunosuppressive treatment, and histology. In 60% of patients, MS begi
ns as a relapsing-remitting disease and evolves secondarily into a pro
gressive neurological illness. Life expectancy is not substantially al
tered in patients with MS, particularly in the early years of the illn
ess. The rate of suicide has been reported to be increased sevenfold i
n MS patients. Up to 40% of patients with attacks severe enough to ren
der them nonambulatory may not recover. At 15 years from MS onset, 50%
of patients are disabled to the point at which they at least require
a cane to walk a half block. Early age at onset, female sex, relapsing
-remitting course at onset, and perhaps optic neuritis or sensory symp
toms at onset and relatively few attacks in the first two years are as
sociated with a favorable course.